For research use only. Not for therapeutic Use.
EMI1 is an EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S inhibitor. EMI1 can be used for the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC)[1].
EMI1 inhibits PC9 EGFR ex19del/T790M/C797S organoid growth with the EC50 of 131 nM[1].
EMI1 (1 nM-10 μM) potently reduces the interaction of EGFR triple mutant with Shc1[1].
EMI1 (1 nM-100μM) strongly inhibits the viability and increase the caspase 3/7 activity of PC9 EGFR ex19del/T790M/C797S triple-mutant cells than noncancerous human bronchial epithelial (HBE) cells[1].
| Catalog Number | I026823 |
| CAS Number | 35773-42-3 |
| Synonyms | 3-(1,3-benzoxazol-2-yl)-7-(diethylamino)chromen-2-one |
| Molecular Formula | C20H18N2O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H18N2O3/c1-3-22(4-2)14-10-9-13-11-15(20(23)25-18(13)12-14)19-21-16-7-5-6-8-17(16)24-19/h5-12H,3-4H2,1-2H3 |
| InChIKey | UJOQSHCJYVRZKJ-UHFFFAOYSA-N |
| SMILES | CCN(CC)C1=CC2=C(C=C1)C=C(C(=O)O2)C3=NC4=CC=CC=C4O3 |
| Reference | [1]. Punit Saraon, et al. A drug discovery platform to identify compounds that inhibit EGFR triple mutants. Nat Chem Biol. 2020 May;16(5):577-586. |
